March 23rd 2023
According to the company, it is the first approval in the world for allogeneic cell therapy to treat corneal endothelial disease.
Novel gene therapy shows promise for treating multiple eye diseases
February 3rd 2023The results are consistent with those observed, and previously published by the same group, showing benefit in age related macular degeneration models and highlights the potential value of ophNdi1 for multiple eye diseases.
Read More
Eyenovia offers results of study evaluating microdose delivery technology
January 12th 2023According to the company, gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride treatment administered via the company’s microdose formulation decreased inflammation from preserved glaucoma solutions compared to drops.
Read More
According to University of California, Irvine researchers, current preclinical successes and clinical genome editing approaches for treating inherited retinal degenerative disease and stresses there is hope that in vivo gene editing will be the future treatment paradigm for these diseases.
Read More
Nanoscope Therapeutics Inc. announced the FDA has granted Fast Track Designation to MCO-010, an ambient-light activatable multi-characteristic opsin optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa via intravitreal injection.
Read More